Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 193

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 193
---
 an 8% annual
rate, and is due upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will
pay to our Chief Executive Officer an aggregate risk premium equal to 30% of the loan amount (or approximately $35,100 plus VAT). If
a registration statement for an initial public offering is made effective no later than March 31, 2025, then the maturity date will be
extended to June 30, 2025. In addition, pursuant to the December 2024 Loan Agreement, upon the consummation of this offering the Company
will issue warrants, or the CEO Loan Warrants, exercisable for a period of three years from the date of the issuance, to purchase such
number of Ordinary Shares equal to two times the respective loan amount divided by 75% of the lowest price per Ordinary Share during
the first five trading days following the consummation of this offering, at an exercise price equal to 75% of the lowest price per Ordinary
Share during the first five trading days following the consummation of this offering. The outstanding debt will become immediately due
and payable upon an event of default (as defined in the December 2024 Loan Agreement), which shall be deemed to have occurred upon certain
circumstances as detailed in the December 2024 Loan Agreement. On March 31, 2025, we and our Chief Executive Officer entered an amendment
to the December 2024 Loan Agreement to extend the maturity date until the earlier of August 31, 2025, or the consummation of an IPO.
On July 1, 2025, we entered into an amendment to the December 2024 Loan Agreement such that our Chief Executive Officer shall be granted
warrants to purchase up to 55,224 Ordinary Shares following the consummation of this offering.

In April 2025, we entered
into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained bridge loans in the aggregate amount of $200,000
from certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors, and Pini Ben Elazar, a director
nominee. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8% per annum until maturity. Pursuant to the terms
of the 2025 Loan Agreements, we also